{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:00:18Z","timestamp":1791925218249,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":573,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF\/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF\/HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with symptomatic HF, left ventricular ejection fraction (LVEF) \u226540%, estimated glomerular filtration rate\u2009\u2265\u200925\u2009ml\/min\/1.73\u2009m2, elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40\u2009mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72\u2009\u00b1\u200910\u2009years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53\u2009\u00b1\u20098% (range 34\u201384%); 36% of participants had a LVEF &amp;lt;50% and 64% had a LVEF \u226550%. The median N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 1041 (interquartile range 449\u20131946) pg\/ml. A total of 1219 (20%) patients were enrolled during or within 7\u2009days of a worsening HF event, and 3247 (54%) patients were enrolled within 3\u2009months of a worsening HF event. Compared with prior large-scale HFmrEF\/HFpEF trials, FINEARTS-HF participants were more likely to have recent (within 6\u2009months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium\u2013glucose cotransporter 2 inhibitors and angiotensin receptor\u2013neprilysin inhibitors than previous trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FINEARTS-HF has enrolled a broad range of high-risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3266","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T05:24:12Z","timestamp":1715405052000},"page":"1334-1346","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D.","family":"Solomon","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9414","authenticated-orcid":false,"given":"John W.","family":"Ostrominski","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University Bicocca Milan, Italy, and, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm Clinical Investigation Centre, CHU , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran Zainal","family":"Abidin","sequence":"additional","affiliation":[{"name":"University of Malaya , Kuala Lumpur ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonio","family":"Alcocer-Gamba","sequence":"additional","affiliation":[{"name":"Centro de Estudios Cl\u00ednicos de Quer\u00e9taro , Quer\u00e9taro ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Atherton","sequence":"additional","affiliation":[{"name":"Cardiology Research Department, Royal Brisbane and Women's Hospital, University of Queensland , Brisbane, QLD ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Sheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Hospital, Capital Medical University , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. Dr. C.C. Iliescu\u2019, University of Medicine Carol Davila , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Chopra","sequence":"additional","affiliation":[{"name":"Clinical Cardiology, Heart Failure and Research, Max Super Specialty Hospital , New Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Comin-Colet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bellvitge University Hospital and Bellvitge Biomedical Research Institute, CIBER-CV, University of Barcelona, L'Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e2ndida","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital S\u00e3o Francisco Xavier, NOVA Medical School, Universidade Nova de Lisboa , Lisbon ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Gajos","sequence":"additional","affiliation":[{"name":"Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College , Krak\u00f3w ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorel","family":"Goland","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Kaplan Medical Center , Rehovot ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Goncalvesov\u00e1","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Comenius University , Bratislava ,","place":["Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Hospital, Yonsei University Health System , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzvetana","family":"Katova","sequence":"additional","affiliation":[{"name":"Department of Noninvasive Cardiology, National Cardiology Hospital , Sofia ,","place":["Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavs","family":"Latkovskis","sequence":"additional","affiliation":[{"name":"Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital , Riga ,","place":["Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Pui-Wai","family":"Lee","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong , Hong Kong ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard C.M.","family":"Linssen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Group Twente , Almelo ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Llamas-Esper\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Cardiologico Aguascalientes , Aguascalientes ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav","family":"Mareev","sequence":"additional","affiliation":[{"name":"University Clinic of Lomonosov Moscow State University , Moscow ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba , C\u00f3rdoba ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojt\u011bch","family":"Melenovsk\u00fd","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM) , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Semmelweis University , Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Brescia and ASST \u2018Spedali Civili\u2019 Hospital , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara In\u00e9s","family":"Saldarriaga","sequence":"additional","affiliation":[{"name":"Centro Cardiovascular Colombiano, Cl\u00ednica Santa Mar\u00eda , Antioquia ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Francisco Kerr","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Instituto de Pesquisa Cl\u00ednica de Campinas , Campinas ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[{"name":"Kawaguchi Cardiovascular and Respiratory Hospital , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte University Hospital , Hellerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Troughton","sequence":"additional","affiliation":[{"name":"Christchurch Heart Institute, Department of Medicine, University of Otago , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Ukkonen","sequence":"additional","affiliation":[{"name":"Heart Centre, Turku University Hospital , Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota, Minneapolis VA Health Care System , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"von Lewinski","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid G.","family":"Voronkov","sequence":"additional","affiliation":[{"name":"National Scientific Center, Strazhesko Institute of Cardiology, National Academy of Medical Sciences , Kyiv ,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Birhan","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Dokuz Eylul University Medical Faculty, Cardiology Department , Izmir ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Max Rady College of Medicine, University of Manitoba , Winnipeg, MB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer plc, Research & Development, Pharmaceuticals , Reading ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"van Gameren","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals , Hoofddorp ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaviana","family":"Amarante","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Bayer, Research & Development, Pharmaceuticals , Whippany, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"2026010913061932600_ejhf3266-bib-0001","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010913061932600_ejhf3266-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913061932600_ejhf3266-bib-0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0004","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with chronic heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0006","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0007","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026010913061932600_ejhf3266-bib-0008","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function","volume":"77","author":"Beldhuis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913061932600_ejhf3266-bib-0009","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by Finerenone-translational aspects and clinical perspectives across multiple organ systems","volume":"23","author":"Kolkhof","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026010913061932600_ejhf3266-bib-0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders \u2013 new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"2026010913061932600_ejhf3266-bib-0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913061932600_ejhf3266-bib-0012","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026010913061932600_ejhf3266-bib-0013","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"2026010913061932600_ejhf3266-bib-0014","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0015","first-page":"384","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0016","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026010913061932600_ejhf3266-bib-0017","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0018","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0019","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysininhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0020","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0021","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: The CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026010913061932600_ejhf3266-bib-0022","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jamacardio.2022.2924","article-title":"Association of empagliflozin treatment with albuminuria levels in patients with heart failure: A secondary analysis of EMPEROR-Pooled","volume":"7","author":"Ferreira","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026010913061932600_ejhf3266-bib-0023","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913061932600_ejhf3266-bib-0024","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026010913061932600_ejhf3266-bib-0025","first-page":"S117","article-title":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"104","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026010913061932600_ejhf3266-bib-0026","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: A prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913061932600_ejhf3266-bib-0027","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/6\/1334\/65512461\/eurjhf_26_6_1334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/6\/1334\/65512461\/eurjhf_26_6_1334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:07:42Z","timestamp":1767982062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/6\/1334\/8328750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,11]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3266","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,11]]},"assertion":[{"value":"2024-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}